HCW Biologics says Phase 1 trial shows hair regrowth signals for HCW9302 in alopecia areata patients

HCW Biologics, Inc.

HCW Biologics, Inc.

HCWB

0.00
  • HCW Biologics reported preliminary Phase 1 human data for HCW9302 monotherapy in alopecia areata from the first two dose cohorts.
  • Results have already been presented in this update; further readouts are expected as dose escalation continues.
  • Patients in the higher of the two completed cohorts showed visible signs of hair-loss improvement following a single injection.
  • The therapy was well tolerated, with no serious safety signals typically associated with IL-2 treatments; most events were mild injection-site reactions.
  • Management targets a recommended Phase 2 dose by year-end 2026, setting up potential Phase 2 studies in alopecia areata.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160700PRIMZONEFULLFEED9747417) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.